
TMC-310911 - Wikipedia
TMC-310911 (also known as ASC-09) is an antiviral drug which was originally researched as a treatment for HIV/AIDS. It is a protease inhibitor related to darunavir .
TMC207: the first compound of a new class of potent anti-tuberculosis drugs
TMC207 is a first-in-class diarylquinoline compound with a novel mechanism of action, the inhibition of bacterial ATP synthase, and potent activity against drug-sensitive and drug-resistant TB. It has bactericidal and sterilizing activity against M. tuberculosis and other mycobacterial species, but little activity against other bacteria.
TMC-310911: Uses, Interactions, Mechanism of Action - DrugBank …
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections....
Recent advances in tuberculosis: New drugs and treatment regimens
Recently completed and ongoing studies involving major drug classes against drug-susceptible (DS-) and drug-resistant (DR-) TB, including multidrug resistant (MDR) and extensively drug resistant (XDR) strains, are described in order to assess the likelihood that new treatment regimens will achieve these goals.
TMC207 becomes bedaquiline, a new anti-TB drug - PubMed
Bedaquiline, formerly TMC207, is a new diarylquinoline antibiotic with specific activity against Mycobacterium tuberculosis and several nontuberculous mycobacteria. It acts by inhibiting ATP synthase, interfering with the energy generation needed by the bacterial cell.
TMC-207 - ScienceDirect
2008年3月1日 · Basic biology information Drug target/mechanism: TMC-207 (R207910, TMC) is a first-in-class diarylquinone, distinct from any marketed compounds. The compound, identified by screening against Mycobacterium smegmatis, has a unique mechanism of action (MOA) targeting the c subunit of ATP synthase.
Public–private partnership tackles TB challenges in parallel
The Global Alliance for TB Drug Development and Tibotec have joined forces to develop a potential first-in-class drug for both drug-susceptible and drug-resistant tuberculosis.
Short-Course Chemotherapy with TMC207 and Rifapentine in a …
2011年9月9日 · TMC207 (TMC, J) is a novel diarylquinoline ATP synthase inhibitor with potent in vitro activity against M. tuberculosis, including strains resistant to commonly used first- and second-line TB drugs ( 9 ). It retains bactericidal activity against slowly replicating or nonreplicating organisms in vitro ( 10 – 12 ).
TMC Pill White Oval 12mm - Pill Identifier - Drugs.com
TMC Pill - white oval, 12mm . Generic Name: etravirine. Pill with imprint TMC is White, Oval and has been identified as Intelence 25 mg. It is supplied by Janssen Pharmaceuticals, Inc. Intelence is used in the treatment of HIV Infection and belongs to the drug class NNRTIs. There is no proven risk in humans during pregnancy.
For drug-susceptible TB, although the current four-drug regimen (isoniazid, rifampin, ethambutol and pyrazinamide) is effective in most cases, the treatment takes 6–9 months because the...
- 某些结果已被删除